Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon L Croft

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
Bioorganic & Medicinal Chemistry|October 15, 2003
2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductaseDidier Pez, Isabel Leal, Fabio Zuccotto, et al.
Wellcome Open Research|January 11, 2019
Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasisHelen Ashwin, Karin Seifert, Sarah Forrester, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2002
In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondiiVanessa Yardley, Anis A Khan, Michael B Martin, et al.
Phytochemistry|August 29, 2003
Cissampeloflavone, a chalcone-flavone dimer from Cissampelos pareiraIrama Ramírez, Alfredo Carabot, Pablo Meléndez, et al.
Journal of Natural Products|July 27, 2002
Isolation and in vitro antiplasmodial activities of alkaloids from Teclea trichocarpa: in vivo antimalarial activity and X-ray crystal structure of normelicopicineMary W Muriithi, W-R Abraham, Jonathan Addae-Kyereme, et al.
Plos Neglected Tropical Diseases|November 27, 2013
Highly sensitive in vivo imaging of Trypanosoma brucei expressing "red-shifted" luciferaseAlex P McLatchie, Hollie Burrell-Saward, Elmarie Myburgh, et al.
Wellcome Open Research|January 25, 2020
Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasisSarah Forrester, Karin Siefert, Helen Ashwin, et al.
International Journal for Parasitology. Drugs and Drug Resistance|July 20, 2019
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasisDiana Caridha, Brian Vesely, Katrien van Bocxlaer, et al.
Frontiers in Pharmacology|November 12, 2025
Comparative <i>in vitro</i> susceptibility of clinical <i>Leishmania</i> isolates to miltefosine and oleylphosphocholineAli Khamesipour, Minoo Tasbihi, Akram Mir Amin Mohammadi, et al.
Journal of Medicinal Chemistry|September 29, 2006
Evaluation of azasterols as anti-parasiticsLudovic Gros, Silvia Orenes Lorente, Carmen Jimenez Jimenez, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Bioorganic & Medicinal Chemistry|October 15, 2003
2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductaseDidier Pez, Isabel Leal, Fabio Zuccotto, et al.
Wellcome Open Research|January 11, 2019
Tissue and host species-specific transcriptional changes in models of experimental visceral leishmaniasisHelen Ashwin, Karin Seifert, Sarah Forrester, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2002
In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondiiVanessa Yardley, Anis A Khan, Michael B Martin, et al.
Phytochemistry|August 29, 2003
Cissampeloflavone, a chalcone-flavone dimer from Cissampelos pareiraIrama Ramírez, Alfredo Carabot, Pablo Meléndez, et al.
Journal of Natural Products|July 27, 2002
Isolation and in vitro antiplasmodial activities of alkaloids from Teclea trichocarpa: in vivo antimalarial activity and X-ray crystal structure of normelicopicineMary W Muriithi, W-R Abraham, Jonathan Addae-Kyereme, et al.
Plos Neglected Tropical Diseases|November 27, 2013
Highly sensitive in vivo imaging of Trypanosoma brucei expressing "red-shifted" luciferaseAlex P McLatchie, Hollie Burrell-Saward, Elmarie Myburgh, et al.
Wellcome Open Research|January 25, 2020
Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasisSarah Forrester, Karin Siefert, Helen Ashwin, et al.
International Journal for Parasitology. Drugs and Drug Resistance|July 20, 2019
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasisDiana Caridha, Brian Vesely, Katrien van Bocxlaer, et al.
Frontiers in Pharmacology|November 12, 2025
Comparative <i>in vitro</i> susceptibility of clinical <i>Leishmania</i> isolates to miltefosine and oleylphosphocholineAli Khamesipour, Minoo Tasbihi, Akram Mir Amin Mohammadi, et al.
Journal of Medicinal Chemistry|September 29, 2006
Evaluation of azasterols as anti-parasiticsLudovic Gros, Silvia Orenes Lorente, Carmen Jimenez Jimenez, et al.
Pageof 15